CoChat

Refining basal insulin therapy: what have we learned in the age of analogues?

DeVries, J. H., Nattrass, M., Pieber, T. R. · 2007 · Diabetes/Metabolism Research and Reviews
Cited by 94

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Background: The basal insulin analogues glargine and detemir have been subject to a series of trials comparing their clinical profiles to the conventional preparation, neutral protamine Hagedorn (NPH). Careful review of these trials provides opportunities to learn clinically useful lessons about these insulins. Methods: MedLine‐indexed trials comparing glargine or detemir to NPH were scrutinized for control, tolerability and dose data. Separate considerations were made for types 1 and 2 diabetes, and for basal–bolus and basal plus oral glucose‐lowering drugs (OGLD) therapy. Attention was paid to dosing schedules and 24‐h glycaemic profiles. Results: Collectively, the trials demonstrated an improved balance between glycaemic control and tolerability for both analogues compared to NPH, regardless of regimen and diabetes type. Neither once‐daily glargine nor detemir reliably provides 24‐h basal insulin replacement in all patients with type 1 diabetes; a waning of effect frequently obliges twice‐daily administration. When added to OGLDs in type 2 diabetes, goal‐titrated once‐daily basal insulin generally lowered HbA 1c by ∼1.5%, whereas twice‐daily administration tended to increase insulin dose disproportionately to improvement in control. Hence, adding bolus insulin may be a preferable intensification method to dividing the basal dose. Varying injection time or dividing the basal insulin dose predictably affects the pattern of hypoglycaemia and bolus dose requirements. Morning administration tends to require higher dosing than evening administration. Conclusions: Scrutiny of trials involving glargine and detemir has increased our understanding of how best to dose basal insulins. An individualized approach is still necessary however, and several questions remain that require further research. Copyright © 2007 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.762

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 94

Metadata

Authors
DeVries, J. H., Nattrass, M., & Pieber, T. R.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2007-07-31
Volume
23
Issue
6
Pages
441-454
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2154661744
Cited by
94
References
15
FWCI
6.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.